Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Restricting abortion drug access

The Supreme Court will soon decide the fate of access for mifepristone. The fallout of a ban would be tremendous

Salon

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

StockNews.com

3 Smart Pharma Picks Serving Gains

With rising healthcare expenditure, growing need for precision medicine, innovations in biologics and gene editing, and rapid adoption of advanced technologies, the pharma industry is well-poised for significant growth and expansion. Thus, quality pharma stocks Wave Life (WVE), Teva Pharmaceuticals (TEVA), and Collegium (COLL) could be smart buys for substantial…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

Britain’s drug shortages are caused by regulator’s failure

Letters: Mark Samuels on why accessing medicines, from routine to life-changing, is getting harder; Philip Clayton wonders why we don’t manufacture our own drugs

The Guardian - UK

Biogen Pulls Controversial Alzheimer's Drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

International Business Times

Merck (MRK): Quarterly Earnings - What Investors Should Know

Pharma giant Merck (MRK) has an impressive record of surpassing analysts’ expectations in its top and bottom lines. So, is the company on track to top estimates in the upcoming earnings release? Let’s discuss some of its financials to gauge its prospects.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Top 3 Pharma Stocks With Bullish Momentum

The pharmaceutical industry’s future appears increasingly optimistic, encouraged by surging healthcare spending due to the rise of chronic and rare disease incidences and an expanding elderly population. The encouraging prognosis of the industry is further bolstered by unwavering ventures into research and development structures and technological advancements. Given this backdrop,…

StockNews.com

Biotech Stock Success: Top 3 Picks for Monthly Gains

Amid the dynamic biotech landscape, the sector is set to witness an upward trajectory fueled by consistent advancements. Therefore, it could be wise to buy fundamentally strong biotech stocks Protalix BioTherapeutics (PLX), Organogenesis Holdings (ORGO), and ANI Pharmaceuticals (ANIP) for monthly gains. Read more.

StockNews.com

Weight-loss Drug Maker Novo Nordisk's Profit Surges As Sales Boom

Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.

International Business Times

GSK surpasses Q4 estimates, projects 2024 growth

GSK's fourth-quarter results exceeded expectations, signaling company growth in 2024. Learn more about the positive financial outlook for GSK.

Top News

Biotech Bulls: 3 Stocks With Buying Potential

The biotech industry's upward trajectory is being fueled by the advancement of orphan medications, innovative biotech equipment, personalized medicine, and robust government support. Thus, biotech stocks ANI Pharmaceuticals (ANIP), Equillium (EQ), and Exelixis (EXEL) might serve as ideal additions to your portfolio. Read more….

StockNews.com

Pharma Buy, Hold, or Sell: 4 Stocks Worth Considering

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

StockNews.com

4 Biotech Stocks With Massive Buy Potential

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Lucrative Biotech Stock Buys for Success

The development of orphan medications, innovative biotech equipment, personalized medicine, and strong government support are all contributing to the biotech industry's upward trajectory. Thus, lucrative biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Organogenesis Holdings (ORGO) could be ideal additions to your portfolio right now. Read more….

StockNews.com

Will These 3 Biotech Stocks Make Gains in 2024?

In the swiftly progressing arena of biotechnology, technological advancements, increasing merger and acquisition maneuvers, and developing product pipelines are driving significant expansion in this sector. The sector's strong potential is further reinforced by a steady demand, ensuring its sustenance. Given this backdrop, let’s analyze whether or not biotech stocks Illumina…

StockNews.com

3 Biotech Stock Gems Bursting With Buy Opportunities

The biotech industry is well poised to flourish, buoyed by its commitment to innovation and potential for groundbreaking discoveries. Thus, investing in the shares of three fundamentally solid biotech companies, Foghorn Therapeutics (FHTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD), might be prudent. Continue reading….

StockNews.com

Buy, Hold, or Sell? Analyzing 3 Biotech Stocks Investors Are Watching

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

More than 10,000 spared GP visit under new trials

A series of trials operating across the nation has allowed 10,000 women to get a new supply of the pill or receive treatment for uncomplicated infections.

StockNews.com

Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

The Guardian - UK

NHS drug shortages are partly a political failure

Letters: Britain is pushing for patent changes in India that could increase the cost of generic drugs, writes Tim Bierley; plus letters from readers on the human cost of shortages

StockNews.com

3 Pharma Stocks to Watch in 2024 for Later Gains

The pharmaceutical industry looks well-positioned for long-term growth. Hence, pharma stocks Procaps Group (PROC), Organon (OGN) and Amphastar (AMPH) might be ideal additions to your watchlists for later gains. Read on.

StockNews.com

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

Kiplinger

2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter

Five pharma companies will have sales that exceed $50 billion this year.

The Guardian - US

Generic drugs in the US are too cheap to be sustainable, experts say

Non-brand-name drugs are one inexpensive part of the healthcare system but they’re driving some manufacturers out of business

1 … 36 37 38 39

People

Dipanjan BanchurSince

722 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.